ERBB2 and breast carcinoma: Furthermore, different from adjuvant chemotherapy, NAC also offers important clinical information, including response to chemotherapeutic agents and pathological complete response (pCR) rate, which has been demonstrated to be a prognostic marker in human epidermal growth factor receptor type 2 (HER2)-positive or triple-negative (TN) breast cancer [2].